

PRESS RELEASE

SANOFI PRESIDENT OF GLOBAL R&D VISITS JHL BIOTECH

October 12th, 2017 –JHL Biotech Inc. (Stock Code: 6540.TWO) is announcing that on Friday, September 29th, 2017, Dr. Elias Zerhouni, President of Global R&D at Sanofi, visited JHL Biotech’s facility in Wuhan, China.

Dr. Zerhouni’s visit in Wuhan was led by JHL Co-Founders Racho Jordanov and Rose Lin. The visit consisted of meetings with JHL senior management to discuss topics of importance to the strategic alliance between JHL and Sanofi, a facility tour, and a meeting with Wuhan government representatives.

In thanking Dr. Zerhouni for visiting JHL, Racho Jordanov said, “JHL and Sanofi are working together to bring world-class biologics to patients around the world. In our meeting with Dr. Zerhouni, the JHL and Sanofi teams discussed ways of accelerating development of biologics and of further integrating development programs at JHL and Sanofi. We look forward to further work with the Sanofi team.”



From Left to Right: Dr. Paul Song, Senior Advisor to the CEO at JHL Biotech; Dr. Peter Pang, Vice President of Clinical and Regulatory Affairs at JHL Biotech; Dennis Wong, Head of Asia Pacific Development at Sanofi; Racho Jordanov, Co-Founder, President, and CEO of JHL Biotech; Rose Lin, Co-Founder and General Manager of Taiwan Operations at JHL Biotech; Dr. Elias Zerhouni, President, Global R&D at Sanofi; Alex Zhang, Head of China R&D at Sanofi; Brianna Han, Scientific Liaison at Sanofi; Annie Teng, Asia Pacific Biologics & Early Development Project Head at Sanofi

End

Media contacts

JHL Biotech, Inc.

Gregory Manker

Phone: +886-909-780-862

gmanker@jhlbiotech.com

About JHL Biotech

JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech's mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. The JHL Center of Excellence in Taiwan does biosimilar pre-clinical and early-clinical phase development. JHL's facility in Wuhan, China executes commercial-scale manufacturing of biologic therapies. This infrastructure gives JHL the unique ability to manufacture its own product and execute contract work on behalf of select clients. For more information, please visit www.jhlbiotech.com.